The 2025 SLD cohort has been selected and the application window is currently closed. Please check back in August 2025 for information about the 2026 application cycle.
ON THIS PAGE
Eligibility | Application Requirements | Example Data Projects | Contact Info
General eligibility criteria
The following is a preview of general eligibility criteria for the program:
- MD, PhD, or equivalent doctoral degree
- Track record of work on HVTN clinical trials
- Need for mentoring in one or more key areas: first authorship, protocol development, protocol implementation, translational research and immunology, statistical analysis
- A local mentor who can oversee their progress
How will scientists be chosen for this program?
- Prior track record of clinical trials research and experience
- Availability of suitable mentor
- Demonstrated evidence of qualities such as intellectual rigor, independence, curiosity, responsibility, drive, and ability to manage multiple priorities
- Track record of supporting colleagues and team approaches to science
Scientists from backgrounds or communities that have been underrepresented in scientific research leadership are particularly encouraged to apply.
Examples of Data Projects
The HVTN has a wealth of data from completed HIV and COVID-19 vaccine trials available to analyze. Below are projects that were undertaken by our inaugural cohort of SLD awardees in 2022-2023:
- Protocol: HVTN 703/HTPN081 and HVTN 704/HPTN085
Analyses of potential relationships between objective solicited adverse events, sex/gender, and VRC01 pharmacokinetics/immune correlates within HVTN 703/HTPN081 and HVTN 704/HPTN085
- Protocol: HVTN 705
Describe the incidence and correlates of pregnancy in participants of HVTN 705, especially contraceptive use, age at time of pregnancy, length of follow up, trial participation
- Protocol: HVTN 702
To evaluate local and systemic reactogenicity signs and symptoms caused by the ALVAC-HIV [Vcp2438] + Bivalent Subtype C gp120/MF59 of HVTN 702 study and identify correlates of reactogenicity
- Protocol: HVTN 704/HPTN 085
Characterize PrEP users, describe correlates of PrEP use compared to others in the trial who did not use PrEP and characterize trial retention between PrEP users and non users
- Protocol: HVTN 703/HPTN 081
Describe STI prevalence, incidence and correlates among women; site-level differences in STI diagnoses and HIV seroconversion
- Protocol: HVTN 704/HPTN 085
Describe STI prevalence, incidence and correlates; site-level differences in STI diagnoses and HIV seroconversion
Other opportunities can be proposed by awardees, especially projects that align with an awardee’s area of interest, projects that allow an awardee to focus on a specific skill, or projects that include protocols with which awardees have been involved.
Francisco Rentas
Fred Hutchinson Cancer Research Center
1100 Eastlake Ave., E3-300
Seattle, WA 98109-1024